Comparison Of Prognostic Factors In Patients With Lung Cancer Operated After Neoadjuvant Treatment.

[AIM] Lung cancer is the leading cause of cancer-related deaths worldwide. The most favorable treatment option for early-stage non-small cell lung cancer is surgical resection. In locally advanced lung cancer, surgery can be performed as part of multimodal treatment regimens. In this study, we aimed to investigate the survival outcomes and prognostic factors of non-small cell lung cancers operated on after neoadjuvant treatment.

[METHODS] The data of patients who were operated on after neoadjuvant treatment in our clinic between 2012 and 2022 were collected. Data were analyzed according to age, gender, complete resection, applied treatment regimen, operation type, presence of viable tumor, histopathology, N status, tumor diameter, and presence of progression.

[RESULTS] A total of 96 patients were included in the study. There were 9 female (9.4%) and 87 male (90.6%) patients. The mean age was 65.2 ± 8.3. Median overall survival was 41 months (15.7-66.2), and 5-year overall survival was 42.4%. Poor prognostic factors for overall survival in our study are being older than 65 years (p=0.02), tumor progressing despite treatment (p=0.008), tumor diameter greater than 2.65 cm (p=0.01), incomplete resection (p=0.002), and tumor stage higher than stage I according to TNM classification 8th edition (p=0.02). There was no significant correlation between survival and gender, tumor histopathology, neoadjuvant treatment protocol, presence of viable tumor, presence of persistent N2, and type of surgery performed (p>0.05) Conclusion: When planning surgery after neoadjuvant treatment in locally advanced lung cancer, there are some parameters to take into consideration which are age, tumor diameter after treatment, complete resectability, and the presence of diameter progression despite treatment.